Sign In
Buy GHRS
$23.61
+1.52 (+6.88%)
At Close: Jun 23, 2026
U.S. stock futures rose in the first full trading week of the year on Monday after closing mixed on Friday. Futures of major benchmark indices were higher.
GH Research: GH001 Shows Robust Data Ahead Of FDA IND Decision
08:30am, Sunday, 04'th Jan 2026
GH Research is advancing GH001, an inhaled mebufotenin therapy for treatment-resistant depression, with a critical FDA IND update imminent. GH001 demonstrated robust Phase 2b efficacy—a 15.5-point M
GH Research to Announce IND Status for GH001
04:01pm, Friday, 02'nd Jan 2026
DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t
Wall Street Analysts Think GH Research (GHRS) Could Surge 130.59%: Read This Before Placing a Bet
10:56am, Monday, 10'th Nov 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 130.6% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the p
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates
07:00am, Thursday, 06'th Nov 2025
Engagement with FDA on GH001 IND complete response ongoing Full dataset from the Phase 2b clinical trial of GH001 in TRD reported in July 2025 Long-term clinical data on safety and efficacy from Open-
Depression-Focused GH Research Shares Could See Significant Upside: Analyst
02:07pm, Monday, 13'th Oct 2025
Needham initiated coverage on Monday for GH Research PLC (NASDAQ:GHRS), citing the company's lead drug candidate, GH-001, which had demonstrated impressive efficacy in Phase 2 versus competition.
GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress
07:00am, Thursday, 09'th Oct 2025
DUBLIN, Oct. 09, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t
GH Research Reports Second Quarter 2025 Financial Results and Provides Business Updates
07:00am, Thursday, 07'th Aug 2025
Global pivotal program initiation on track for 2026 Engagement with FDA on GH001 IND complete response ongoing The fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 mont
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate
04:38pm, Wednesday, 23'rd Jul 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and e
atai Life Sciences poised to lead treatment-resistant depression market with psychedelic candidate BPL-003
01:08pm, Wednesday, 23'rd Jul 2025
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) is gaining momentum in the psychedelics space, with Jefferies analysts highlighting the company's potential to leapfrog rival GH Research (NASDAQ:GHRS) and e
GH Research Announces Global Pivotal Program Plans and Further Development Updates
08:00am, Wednesday, 23'rd Jul 2025
DUBLIN, July 23, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t
Wall Street Analysts Believe GH Research (GHRS) Could Rally 107.25%: Here's is How to Trade
10:56am, Wednesday, 16'th Jul 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 107.3% in GH Research (GHRS). While the effectiveness of this highly sought-after metric is questionable, the p
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
01:00pm, Friday, 20'th Jun 2025
DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing t
DUBLIN, May 15, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing tr
GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates
07:00am, Thursday, 08'th May 2025
DUBLIN, May 08, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing tr
